Imperative Care announced today that it received FDA 510(k) clearance for its novel Zoom 7X catheter for aspiration thrombectomy procedures.
The company also reported the first patient cases with its latest advancement for ischemic stroke treatment. Campbell, California-based Imperative Care said it marks the first catheter to incorporate its CenTRX technology. This unique, 96-degree, pre-shaped tip centers in the vessel. This helps to maximize clot ingestion with the extra surface area of the asymmetric tip.
Zoom 7X adds another option to the wide-ranging Zoom aspiration system portfolio. Imperative Care designed Zoom for fast and effective clot removal from access through reperfusion. It treats patients with acute ischemic stroke, enabling smooth tracking through challenging vasculature.
Imperative Care believes its proprietary feature allows the device to navigate challenging anatomy. It can self-orient the geometric tip into the optimal position for full clot aspiration. The company says this builds upon the benefits of asymmetric aspiration in stroke.
“Based on direct feedback from physicians, the Zoom 7X Catheter was developed to address the need for even greater trackability, navigation and asymmetric clot ingestion,” said Ariel Sutton, GM of Imperative Care Stroke. “Zoom 7X builds upon our comprehensive system of stroke technologies with the goal of making the procedure faster, safer and more efficient than ever before. The launch of Zoom 7X, paired with the recent introduction of the continuous dual aspiration technique (CDAT) with Zoom DuoPort, advances the field one step closer to making TICI 3 in 10 minutes the expectation for physicians.”
